Thomas Blankenburg

475 total citations
20 papers, 384 citations indexed

About

Thomas Blankenburg is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Endocrine and Autonomic Systems. According to data from OpenAlex, Thomas Blankenburg has authored 20 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 3 papers in Endocrine and Autonomic Systems. Recurrent topics in Thomas Blankenburg's work include Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Thomas Blankenburg is often cited by papers focused on Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Thomas Blankenburg collaborates with scholars based in Germany, Austria and United Kingdom. Thomas Blankenburg's co-authors include Wolfgang Schuette, S. Nagel, H Schweisfurth, K. Hans, Angelika Reißig, Monika Serke, Ludwig Fischer von Weikersthal, Christine Lautenschlaeger, Aruna Raghavachar and Wolfgang Schütte and has published in prestigious journals such as Journal of Clinical Oncology, Biometrical Journal and Strahlentherapie und Onkologie.

In The Last Decade

Thomas Blankenburg

19 papers receiving 366 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Blankenburg Germany 10 270 208 43 40 34 20 384
Meinrad Mannhart Switzerland 9 132 0.5× 304 1.5× 52 1.2× 45 1.1× 76 2.2× 19 413
Hui-Wen Weng China 9 133 0.5× 122 0.6× 28 0.7× 125 3.1× 45 1.3× 14 371
Diego Kauffmann‐Guerrero Germany 11 264 1.0× 279 1.3× 59 1.4× 91 2.3× 18 0.5× 59 459
Melissa A.L. Vyfhuis United States 10 201 0.7× 182 0.9× 24 0.6× 28 0.7× 35 1.0× 30 390
Kosuke Kashiwabara Japan 12 245 0.9× 111 0.5× 19 0.4× 37 0.9× 35 1.0× 36 340
Geòrgia Anguera Spain 11 116 0.4× 136 0.7× 19 0.4× 76 1.9× 37 1.1× 43 281
L. Bigay-Gamé France 10 193 0.7× 126 0.6× 43 1.0× 72 1.8× 26 0.8× 32 343
Scott P. Tannehill United States 8 128 0.5× 122 0.6× 42 1.0× 35 0.9× 163 4.8× 15 464
Robert Díaz Beveridge Spain 11 139 0.5× 172 0.8× 45 1.0× 35 0.9× 63 1.9× 43 317
Takashi Oishi Japan 7 242 0.9× 114 0.5× 49 1.1× 35 0.9× 68 2.0× 18 343

Countries citing papers authored by Thomas Blankenburg

Since Specialization
Citations

This map shows the geographic impact of Thomas Blankenburg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Blankenburg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Blankenburg more than expected).

Fields of papers citing papers by Thomas Blankenburg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Blankenburg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Blankenburg. The network helps show where Thomas Blankenburg may publish in the future.

Co-authorship network of co-authors of Thomas Blankenburg

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Blankenburg. A scholar is included among the top collaborators of Thomas Blankenburg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Blankenburg. Thomas Blankenburg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blankenburg, Thomas, et al.. (2017). Survival of Hypercapnic Patients with COPD and Obesity Hypoventilation Syndrome Treated with High Intensity Non Invasive Ventilation in the Daily Routine Care. The Open Respiratory Medicine Journal. 11(1). 31–40. 12 indexed citations
2.
3.
Wilkens, Heinrike, Iréne Lang, Thomas Blankenburg, et al.. (2014). Chronisch thromboembolische pulmonale Hypertonie (CTEPH) 2014 (Kurzversion). DMW - Deutsche Medizinische Wochenschrift. 139(43). 2204–2206. 2 indexed citations
4.
Wilkens, Heinrike, Iréne Lang, Thomas Blankenburg, et al.. (2014). Chronisch thromboembolische pulmonale Hypertonie (CTEPH) 2014 (Langversion). DMW - Deutsche Medizinische Wochenschrift. 139(S 04). S155–S165. 5 indexed citations
5.
Blankenburg, Thomas, et al.. (2012). Six‐minute walk distance and dyspnoea scores to assess the course of COPD exacerbation in elderly patients. The Clinical Respiratory Journal. 7(3). 261–267. 9 indexed citations
6.
Evers, Josef, et al.. (2010). Influence of NaCl 0.9% Infusion during Plasmapheresis on IgG Content in Plasma. Transfusion Medicine and Hemotherapy. 37(4). 191–194. 4 indexed citations
7.
Blankenburg, Thomas, Birgit Gottschlich, W. Schütte, H Neef, & Johannes Haerting. (2010). Prognostische Relevanz der Metastasenlokalisation bei nicht kleinzelligem Bronchialkarzinom im Tumorstadium IV – Ergebnisse einer prospektiven epidemiologischen Studie. Pneumologie. 64(11). 679–685. 1 indexed citations
8.
Magnussen, H, David F. Heigener, Claudia Bausewein, et al.. (2009). Palliativmedizin in der Pneumologie. Pneumologie. 63(5). 289–295.
9.
Nagel, S., Chia‐Jung Busch, Thomas Blankenburg, & Wolfgang Schütte. (2009). Behandlung der respiratorischen Papillomatose – Kasuistik zur systemischen Therapie mit Bevacizumab. Pneumologie. 63(7). 387–389. 26 indexed citations
10.
Kuß, Oliver, Thomas Blankenburg, & Johannes Haerting. (2008). A Relative Survival Model for Clustered Responses. Biometrical Journal. 50(3). 408–418. 7 indexed citations
11.
Blankenburg, Thomas, Michael Flentje, Godehard Friedel, Rudolf M. Huber, & Hans Tesch. (2006). Konzepte zur Qualitätssicherung im Management des Lungenkarzinoms. Onkologie. 29(2). 20–24. 1 indexed citations
12.
Schuette, Wolfgang, Thomas Blankenburg, Claus-Peter Schneider, et al.. (2006). Randomized, Multicenter, Open-Label Phase II Study of Gemcitabine plus Single-Dose Versus Split-Dose Carboplatin in the Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 8(2). 135–139. 3 indexed citations
13.
Schuette, Wolfgang, Thomas Blankenburg, Michael Schneider, et al.. (2006). Multicenter Randomized Trial for Stage IIIB/IV Non–Small-Cell Lung Cancer Using Every-3-Week Versus Weekly Paclitaxel/Carboplatin. Clinical Lung Cancer. 7(5). 338–343. 39 indexed citations
14.
15.
Schuette, Wolfgang, et al.. (2005). Clinical Benefit in NSCLC: Advanced-Stage Patients Require Symptom-Improving Palliation. Experiences from the ‘Iressa’ Expanded Access Program. Oncology Research and Treatment. 28(4). 195–198. 16 indexed citations
16.
Schuette, Wolfgang, et al.. (2005). Phase II Trial of Gemcitabine/Irinotecan in Refractory or Relapsed Small-Cell Lung Cancer. Clinical Lung Cancer. 7(2). 133–137. 23 indexed citations
17.
Schuette, Wolfgang, S. Nagel, Thomas Blankenburg, et al.. (2005). Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel. Journal of Clinical Oncology. 23(33). 8389–8395. 156 indexed citations
18.
Blankenburg, Thomas, et al.. (2004). Survival of Patients in Clinical Stages I–IIIb of Non-Small-Cell Lung Cancer Treated with Radiation Therapy Alone. Strahlentherapie und Onkologie. 180(8). 488–496. 11 indexed citations
19.
20.
Schuette, Wolfgang, et al.. (2003). A Multicenter Phase II Study of Gemcitabine and Oxaliplatin for Malignant Pleural Mesothelioma. Clinical Lung Cancer. 4(5). 294–297. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meinrad Mannhart Breakdown of academic impact, for papers by Hui-Wen Weng Breakdown of academic impact, for papers by Diego Kauffmann‐Guerrero Breakdown of academic impact, for papers by Melissa A.L. Vyfhuis Breakdown of academic impact, for papers by Kosuke Kashiwabara Breakdown of academic impact, for papers by Geòrgia Anguera Breakdown of academic impact, for papers by L. Bigay-Gamé Breakdown of academic impact, for papers by Scott P. Tannehill Breakdown of academic impact, for papers by Robert Díaz Beveridge Breakdown of academic impact, for papers by Takashi Oishi
Rankless by CCL
2026